Related Experiment Videos
Bromocriptine therapy in eleven patients with acromegaly
Acta Endocrinologica. Supplementum
|January 1, 1978
Summary
Bromocriptine treatment significantly reduced growth hormone and improved symptoms in patients with acromegaly. This study found bromocriptine to be a safe and effective treatment option for acromegaly over one year.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Acromegaly is a hormonal disorder caused by excess growth hormone (GH) production.
- Effective treatments are crucial for managing acromegaly and preventing complications.
Purpose of the Study:
- To evaluate the efficacy and safety of bromocriptine in patients with active acromegaly.
Main Methods:
- Eleven patients with active acromegaly were enrolled.
- Treatment with bromocriptine was administered for at least one year.
Main Results:
- Nine out of eleven patients demonstrated a significant reduction in plasma growth hormone levels.
- Eight patients experienced improvement in clinical symptoms associated with acromegaly.
- No serious adverse events were reported during the treatment period.
Conclusions:
- Bromocriptine is an effective therapeutic option for managing acromegaly.
- Long-term bromocriptine treatment leads to significant clinical and biochemical improvements.
- Bromocriptine exhibits a favorable safety profile in acromegaly patients.